20% off purchase of 3 or more products* | Learn More >>

Monkey Artery Morphogenesis

$269
100 µl
APPLICATIONS
REACTIVITY
Human, Monkey, Mouse, Rat

Application Methods: Immunohistochemistry (Paraffin), Immunoprecipitation, Western Blotting

Background: HES1 (Hairy and Enhancer of Split 1) is one of seven members of the HES family of basic helix-loop-helix (bHLH) transcription factors which function primarily to repress transcription of bHLH-dependent genes (1). HES1 is understood to play an important conserved role in maintaining pluripotency of embryonic and adult stem/progenitor cells via the transcriptional repression of genes that promote differentiation (1,2). HES1 is particularly well known as a repressive mediator of the canonical Notch signaling pathway (3). HES1 plays a key role in mediating Notch-dependent T cell lineage commitment (4), and has been reported to be an essential mediator of Notch-induced T cell acute lymphoblastic leukemia (T-ALL) (4,5). HES1 is also reported to mediate Notch-induced repression of differentiation in a number of cancer cell types. A conditional deletion of HES1 from intestinal tumor cells in APC-mutant mice reduced tumor cell proliferation, while promoting differentiation toward epithelial lineages (6). Overexpression of HES1 in a human osteosarcoma (OS) cell line was shown to repress expression of the Notch antagonist Dtx1, leading to increased OS cell invasiveness (7). Other genes subject to transcriptional repression by HES1 include Neurogenin-2, Math1/Atoh1 and the NOTCH ligands DLL1 and Jagged1 (6,8,9).

$269
100 µl
APPLICATIONS
REACTIVITY
Human, Monkey, Mouse

Application Methods: Immunohistochemistry (Paraffin), Immunoprecipitation, Western Blotting

Background: ZMIZ1, also known as ZIMP10 or RAI17, is a member of the Protein Inhibitor of Activated STAT (PIAS)-like family of transcriptional coregulators (1). ZMIZ1 was initially discovered as a novel coregulator of the androgen receptor (AR) and was shown to augment AR activity by enhancing sumoylation of the receptor (2). Subsequent studies have shown that ZMIZ1 can also act as a transcriptional coactivator of p53 (3) and SMAD3 (4). During thymopoiesis, ZMIZ1 was shown to promote pre-T-cell proliferation through cooperative induction of a subset of NOTCH target genes (5). In T-cell acute lymphoblastic leukemia (T-ALL) cells, ZMIZ1 was shown to engage directly with NOTCH1 through an N-terminal tetratricopeptide repeat (TPR) domain, facilitating its recruitment to a long-range acting enhancer element to promote MYC transcription and activity. Moreover, inhibition of ZMIZ1 impaired the initiation and maintenance of NOTCH-induced T-ALL (6). Although NOTCH1 appears to rely on ZMIZ1 to selectively amplify an oncogenic subset of target genes, research studies suggest ZMIZ1 is not involved in NOTCH-mediated intestinal homeostasis or myeloid suppression, suggesting that therapeutic strategies targeting ZMIZ1 may provide an opportunity to indirectly target NOTCH-driven cancers, with reduced adverse effects (7).

$260
100 µl
APPLICATIONS
REACTIVITY
Human, Monkey, Mouse, Rat

Application Methods: Immunoprecipitation, Western Blotting

Background: Neurofibromin is a Ras-specific GTPase activating protein (RasGAP), down-regulating Ras signaling (1). Studies have shown, that mutations in NF1 inhibit its activity, resulting in benign tumors such as neurofibromas, which may form along nerves throughout the body resulting in neurofibromatosis type 1 (NF1) (2). NF1 is one of the most common autosomal dominant diseases however it remains unclear how mutation of NF1 may lead to other features of NF1 (3). In addition, NF1 mutations occur in 5-10% of human sporadic malignancies such as glioblastomas, lung adenocarcinomas, melanomas, breast and ovarian cancers, and acute myeloid leukemias. Mutations in NF1 can cause resistance to therapies including chemotherapy and radiation therapy (3).

$307
100 µl
$719
300 µl
APPLICATIONS
REACTIVITY
Human, Monkey, Mouse, Rat

Application Methods: Immunoprecipitation, Western Blotting

Background: Glycogen synthase kinase-3 (GSK-3) was initially identified as an enzyme that regulates glycogen synthesis in response to insulin (1). GSK-3 is a ubiquitously expressed serine/threonine protein kinase that phosphorylates and inactivates glycogen synthase. GSK-3 is a critical downstream element of the PI3K/Akt cell survival pathway whose activity can be inhibited by Akt-mediated phosphorylation at Ser21 of GSK-3α and Ser9 of GSK-3β (2,3). GSK-3 has been implicated in the regulation of cell fate in Dictyostelium and is a component of the Wnt signaling pathway required for Drosophila, Xenopus, and mammalian development (4). GSK-3 has been shown to regulate cyclin D1 proteolysis and subcellular localization (5).

$303
100 µl
APPLICATIONS
REACTIVITY
Human, Monkey, Mouse, Rat, Zebrafish

Application Methods: Western Blotting

Background: Glycogen synthase kinase-3 (GSK-3) was initially identified as an enzyme that regulates glycogen synthesis in response to insulin (1). GSK-3 is a ubiquitously expressed serine/threonine protein kinase that phosphorylates and inactivates glycogen synthase. GSK-3 is a critical downstream element of the PI3K/Akt cell survival pathway whose activity can be inhibited by Akt-mediated phosphorylation at Ser21 of GSK-3α and Ser9 of GSK-3β (2,3). GSK-3 has been implicated in the regulation of cell fate in Dictyostelium and is a component of the Wnt signaling pathway required for Drosophila, Xenopus, and mammalian development (4). GSK-3 has been shown to regulate cyclin D1 proteolysis and subcellular localization (5).

$111
20 µl
$260
100 µl
APPLICATIONS
REACTIVITY
Hamster, Human, Monkey, Mouse, Rat

Application Methods: Immunoprecipitation, Western Blotting

Background: Glycogen synthase kinase-3 (GSK-3) was initially identified as an enzyme that regulates glycogen synthesis in response to insulin (1). GSK-3 is a ubiquitously expressed serine/threonine protein kinase that phosphorylates and inactivates glycogen synthase. GSK-3 is a critical downstream element of the PI3K/Akt cell survival pathway whose activity can be inhibited by Akt-mediated phosphorylation at Ser21 of GSK-3α and Ser9 of GSK-3β (2,3). GSK-3 has been implicated in the regulation of cell fate in Dictyostelium and is a component of the Wnt signaling pathway required for Drosophila, Xenopus, and mammalian development (4). GSK-3 has been shown to regulate cyclin D1 proteolysis and subcellular localization (5).

$303
100 µl
APPLICATIONS
REACTIVITY
Hamster, Human, Monkey, Mouse, Rat

Application Methods: Immunoprecipitation, Western Blotting

Background: Glycogen synthase kinase-3 (GSK-3) was initially identified as an enzyme that regulates glycogen synthesis in response to insulin (1). GSK-3 is a ubiquitously expressed serine/threonine protein kinase that phosphorylates and inactivates glycogen synthase. GSK-3 is a critical downstream element of the PI3K/Akt cell survival pathway whose activity can be inhibited by Akt-mediated phosphorylation at Ser21 of GSK-3α and Ser9 of GSK-3β (2,3). GSK-3 has been implicated in the regulation of cell fate in Dictyostelium and is a component of the Wnt signaling pathway required for Drosophila, Xenopus, and mammalian development (4). GSK-3 has been shown to regulate cyclin D1 proteolysis and subcellular localization (5).